Gambro sales up 4%, sale to DaVita on track
This article was originally published in Clinica
Executive Summary
Swedish renal care group Gambro reported a 4% increase in revenues to SKr3.36bn ($477m) in the first quarter, excluding the SKr3.28bn (-2%) generated by Gambro Healthcare US, which the company is selling to DaVita of California. Gambro said it was difficult to predict the timing of the US Federal Trade Commission's appraisal of the transaction, but that DaVita was in talks with the FTC and it continued to "estimate that an agreement will be reached during the second quarter".